Zura Bio Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZURA research report →
Range $20 – $20
Price Chart
About the company
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
- CEO
- Sandeep C. Kulkarni
- IPO
- 2023
- Employees
- 40
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on ZURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $546.24M
- P/E
- -5.09
- PEG
- 0.10
- P/S
- 0.00
- P/B
- 3.70
- EV/EBITDA
- -3.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.98%
- ROIC
- -47.02%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-75,246,000
- Net Income
- $-68,650,000-31.0%
- EPS
- $-1.06-76.7%
- OCF Growth
- -130.9%
- FCF Growth
- -130.6%
- 52W High
- $7.44
- 52W Low
- $1.78
- 50D MA
- $5.09
- 200D MA
- $5.12
- Beta
- -0.04
- RSI (14)
- 56
- Avg Volume
- 1.09M
No earnings-call transcripts are available for ZURA yet.
- Free Float
- 53.4%
- Shares Outstanding
- 95.00M
- Float Shares
- 50.75M
of shares held by institutions
80 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 568.12K | ▲ 50.97K |
| Two Sigma Advisers, LP | 80.40K | ▼ 38.70K |
| Cubist Systematic Strategies, LLC | 49.36K | ▲ 27.86K |
| Point72 Asia (Singapore) Pte. Ltd. | 18.42K | ▼ 12.13K |
| Clear Street LLC | 1.68K | 0 |
| Cwm, LLC | 116 | ▼ 26 |
Held by 18 ETFs
Biggest fund positions in ZURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 11,133 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 90,000 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 81,150 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 66,220 |
| Jun 17, 26 | Jarrett Jennifer | other | 51,000 |
| Jun 17, 26 | Thiara Parvinder | other | 51,000 |
| Jun 17, 26 | Schoch Steven J | other | 51,000 |
| Jun 17, 26 | Nirula Ajay | other | 51,000 |
| Jun 17, 26 | Munshi Amit | other | 51,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZURA coverage
Recent articles, reports, and earnings notes.
No research on ZURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZURA report →Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
gurufocus.com · Aug 11
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
businesswire.com · Aug 11
Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages
defenseworld.net · Jul 26
Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why
defenseworld.net · Jul 19
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy
benzinga.com · Jul 8
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
businesswire.com · Jun 29
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · May 14
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
businesswire.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.